ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today shared the company’s commitment to make at least two million doses of long-acting cabotegravir for HIV pre-exposure prophylaxis (CAB LA for PrEP) available for procurement for low- and middle-income countries (L&MICs) during 2025-2026. The new commitment will triple the company’s available supply versus 2024, to accelerate access and meet growing demand where the HIV burden and unmet need are greatest. The announcement was made at the HIV R4P 2024 conference, being held in Lima, Peru from 6-10 October.

Additional information to the following link: ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries | GSK